Xiaolan Hu
About Xiaolan Hu
Xiaolan Hu is the Head of Clinical Genetics at Bristol-Myers Squibb in the Greater New York City Area, with over a decade of experience in clinical genetics and personalized medicine.
Professional Experience at Bristol-Myers Squibb
Xiaolan Hu currently serves as the Head of Clinical Genetics, DMCP at Bristol-Myers Squibb. Based in the Greater New York City Area, she has been leading the clinical genetics team since January 2012. During her tenure, she has overseen multiple initiatives aimed at advancing the field of clinical genetics, leveraging her extensive background in both biology and computer science.
Past Roles at Pfizer Pharmaceuticals
Before her current role, Xiaolan Hu worked at Pfizer Pharmaceuticals from 2007 to 2012 as an Associate Director. During her five-year tenure, she played a key role in advancing personalized medicine initiatives. Her work contributed to the development and implementation of new genetic testing protocols aimed at improving patient outcomes.
Experience at Genentech and Celera
Xiaolan Hu also gained experience at Genentech and Celera. At Genentech, she served as an Associate Scientist from 2005 to 2007, where she contributed to developing genetic testing protocols. Prior to that, she was a Senior Scientist at Celera from 2002 to 2005, working on significant genetic research projects that have had a lasting impact on the field of clinical genetics.
Educational Background
Xiaolan Hu has an extensive educational background in both computer science and biology. She earned a Ph.D. in Biology and an M.S. in Computer Science from Brown University, where she studied from 1997 to 2002. Before that, she obtained her B.S. in Genetics from Peking University, studying from 1991 to 1996. Her interdisciplinary education uniquely positions her to bridge the gap between computational and biological research.
Industry Contributions and Publications
Xiaolan Hu has contributed to several high-impact publications in the field of genetics. She actively participates in industry conferences and seminars related to clinical genetics and personalized medicine. Her work has significantly advanced the field, making her a respected figure in both academic and industry circles.